Chronic rhinosinusitis with nasal polyps as a major comorbid disease in severe asthma patients: Evidence from severe asthma registry of Kuwait

Abstract

The clinical and laboratory features of patients enrolled in the severe asthma registry in Kuwait were evaluated, with special emphasis on chronic rhinosinusitis with nasal polyposis (CRSwNP). The following information were collected from ongoing severe asthma registry from Kuwait: demographic data, clinical features, asthma control test in the previous month and treatment for severe asthma patients (ATS/ERS criteria). 311 patients with severe asthma enrolled in severe asthma registry of Kuwait and 141 patients has comorbid CRSwNP. Mean age of patients was 43.3 years, SD 12.7. Although 93.6% of patients with CRSwNP were eligible for biological therapy, 56% (79 patients) received biologic therapy. The most common biologic therapy was Dupilumab. The use of biologics significantly improved oral corticosteroid (OCS) use (frequently used in 84 CRSwNP patients (59.6%) in the previous year into 98.7% of patients with no OCS use after biologic initiation). OCS sparing is required in patients with CRSwNP or severe asthma. The use of targeted biologic therapy significantly improved treatment outcome.